Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
FAIL · Does not pass the screen
114.41 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price114.41 USD at the 6 Nov 2026 close
Our value readFair vs our fair value, as of 6 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.10, read 2026-11-01
Ethical does not pass the values gate
Price114.41 USD
Fair value104.70
Ethical score70.0/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-11-05Read Markup110.00+4.0% to today ✓Markdown gives way to Markup after a 14% rise in 3 weeks
2026-10-18Read Markdown96.79+18.2% to today Distribution gives way to Markdown first Markdown read since October
2026-10-11Read Distribution101.74+12.4% to today Markdown gives way to Distribution after a 16% slide in 9 days
2026-10-02Read Markdown121.00-5.5% to today ✓Markup gives way to Markdown first Markdown read since August
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Insmed Inc holds its Markup at $114.41. The statistical read favours the sellers, held for 1 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 1 days
Price at the screen
$114.41
Valuation
N/A trailing · 174.81 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.81
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
25.91%
Below 33%
Interest-bearing debt is just 25.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
40.61%
Below 33%
Interest-bearing cash and securities are 40.6% of assets, above the one-third limit.
Fail
Receivables
28.76%
Below 49%
Money owed to the company is 28.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Insmed's business is fine, but its cash and interest-bearing securities are about 41% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when INSM's ethical verdict changes
Today INSM does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: it trades above our $104.70 fair value estimate, narrow competitive moat, 268.40% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. The price runs 9.3% above the base estimate.
Third-party analyst targets: 22 covering, consensus Strong Buy. The average target sits +70% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $104.70, with a range of $104.70 to $120.40, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare disease biotech priced for perfection
A patient in Japan finally clearing a stubborn lung infection marks real progress for families who had few options before. Insmed is delivering that progress, with revenue up 230 percent as its lead therapy gains ground across the US, Europe and Japan.
Yet the shares sit 6 percent above our fair value at an 814 times forward multiple while margins sit at minus 144 percent and return on equity at minus 294 percent. Narrow moat and strong buy analyst targets do not change the fact that current pricing leaves almost no margin of safety.
Execution risk in rare disease trials, regulatory delays abroad and the need to turn rapid top line growth into actual profits remain the central concerns. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
INSM trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup · changed$110.00+17.8%Entry 17
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 17.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197.
2026-10-29Markdown$93.39+0.0%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$93.39+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$93.39+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$93.39+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$93.39+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$93.39-3.5%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$96.79+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown$96.79+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown · changed$96.79-4.9%Entry 8
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
